Uterine leiomyoma is the most common type of benign neoplasm in the female reproductive system, and is the most common indication for hysterectomy in premenopausal women.
However, there were no difference in BPA levels between a group of women with simple endometrial hyperplasia and a control group, 4 while Newbold et al. 5 found that exposure to BPA for 18 months increased the occurrence of myoma in mice. Elucidating the relationship between BPA and the development of uterine leiomyoma will be invaluable for reducing the incidence and size of uterine leiomyomas in women. We investigated human BPA exposure levels by measuring serum BPA levels in women with uterine leiomyomas and the relationship between BPA level and leiomyoma growth by stratifying women according to leiomyoma size.
Material and Methods
The subjects of this study were 200 women who visited After incubation, the mixtures were processed with an Isolute M-M column (sorbent mass: 500 mg, reservoir volume: 3 mL; Biotage), which was pretreated with 10 mL methanol and 6 mL distilled water. The column was cleaned with 6 mL 35% methanol, and eluted with 2.5 mL 100%
methanol. The nitrogen gas was uniformly evaporated by eluted methanol, and the sample extract was then adjusted to contain 10% methanol by mixing it with 10 μ L of 100% methanol. BPA from the sample, which was dissolved in methanol, was analyzed. 
Results
The total number of samples was 158, including 48 in the mild group, 32 in the moderate group, 28 in the severe group, and 50 in the control group. There were no statistically significant differences in the mean age or body mass index (BMI) among each group (each, P = 0.836, P = 0.854) ( Table 1 ). Table 1) .
The mean ± standard deviation of the BPA level for all subjects was 0.448 ± 0.047 ng/mL. There was no significant difference in the mean ± standard deviation of the BPA level between the uterine leiomyoma group (0.403 ± 0.049 ng/mL) and the control group (0.558 ± 0.097 ng/ mL) (P = 0.08). However, there were significant differences in the mean ± standard deviation of the BPA level among the control group and three subgroups, the latter of which had 0.274 ± 0.063 ng/mL in the mild group, 0.346 ± 0.064 ng/mL in the moderate group, and 0.647 ± 0.039 ng/mL in the severe group (P = 0.0003) ( Table 1 ).
The average level of BPA in the control group was significantly higher than the level in the mild and the moderate groups by post-hoc multiple comparisons (each, P = 0.007, P = 0.03). The average level of BPA in the severe group was also significantly higher than the mild and the moderate groups by post-hoc multiple comparisons (each, P = 0.0001, P = 0.003). However, there were no significant differences in the average level of BPA between the control group and the severe group or between the mild group and the moderate group (each, P = 0.48, P = 0.43).
Discussion
Estrogens exhibit biologic effects via estrogen receptors Mean ± standard deviation, *mean ± standard error, † non-detected. BMI: body mass index, BPA: bisphenol A duces estrogen ablation, which decreases the size of uterine leiomyomas. This shows that leiomyoma cells are hypersensitive to estrogen stimulation. Therefore, leiomyomas are a potential target of endocrine disruption by xeno-estrogens. It is important to understand that xeno-estrogens act as agonists on the myometrium via the estrogen receptors. In the present study, we assessed the relationship between uterine leiomyoma and BPA levels in the blood. Although there were no differences in the blood BPA level among groups, some statistical differences were present among subgroups classified by size of uterine leiomyoma; the more severe the uterine leiomyoma was, the higher the average level of BPA. This is the first multi-center trial to investigate BPA levels in uterine leiomyoma patients. However, we are limited in our ability to conclude there is a causal relationship between existing uterine leiomyoma and BPA level in the blood. To further examine the pathogenesis of uterine leiomyoma, a closer look at high risk subjects and sequential studies are needed, and many factors related to uterine leiomyoma incidence should be considered. Additional studies are also needed to clarify the identification of the molecular mechanisms that determine agonist activity on the myometrium of the uterus. Furthermore, studies of the relationships between BPA and other gynecological disorders, such as adenomyosis are needed.
